Company Profile
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Latest News
Revvity Develops High-Throughput T-SPOT.TB Platform for Clinical Labs
Revvity to Launch Signals for Startups for Emerging Biotech Companies
Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure
ASML Holding N.V. Upgraded, Super Micro Computer Downgraded: Updated Rankings on Top Blue-Chip Stocks
Revvity Launches "Signals for Startups" to Help Emerging Biotechs Build Scalable Digital Foundations from Day One
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Website | https://www.revvity.com |
| Audit Risk | 9 |
| Board Risk | 2 |
| Overall Risk | 6 |
| Market Cap | 12.32B |
| Trailing P/E | 53.11 |
| Forward P/E | 18.95 |
| Dividend Rate | 0.28 |
| Dividend Yield | 0.25% |
| Trailing Annual Div. Rate | 0.28 |
| Trailing Annual Div. Yield | 0.25% |
| Trailing EPS | 2.08 |
| Forward EPS | 5.83 |
| Book Value | 64.35 |
| Price-to-Book | 1.72 |
| Enterprise-to-Revenue | 5.1 |
| Enterprise-to-EBITDA | 17.32 |
| Short Ratio | 5.09 |
| Ex-Dividend Date | 07/17/2026 |
| Dividend Date | 08/07/2026 |
| Earnings Date | 08/04/2026 |
| Earnings Call Date | 08/04/2026 |
| Earnings Average | 1.22 |
| Earnings Low | 1.19 |
| Earnings High | 1.28 |
| Revenue Average | 703.18M |
| Revenue Low | 696.00M |
| Revenue High | 706.00M |